Organogenesis (NASDAQ:ORGO) Given "Buy" Rating at BTIG Research

Key Points

• BTIG Research has reaffirmed a "Buy" rating for Organogenesis (NASDAQ:ORGO) with a target price of $7.00, indicating a potential upside of 49.57% from its recent close.
• Cantor Fitzgerald has raised Organogenesis’s target price from $7.00 to $9.00 and assigned an "overweight" rating, contributing to a consensus rating of "Moderate Buy."
• Organogenesis reported a quarterly loss of ($0.09) earnings per share, missing estimates, along with a revenue of $101.01 million, below analyst expectations of $104.75 million.

Organogenesis (NASDAQ:ORGO - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at BTIG Research in a note issued to investors on Friday,Benzinga reports. They currently have a $7.00 price objective on the stock. BTIG Research's target price would suggest a potential upside of 49.57% from the stock's previous close.

Separately, Cantor Fitzgerald upped their target price on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.33.

Organogenesis Stock Performance

NASDAQ:ORGO opened at $4.68 on Friday. The stock has a market cap of $593.70 million, a price-to-earnings ratio of -33.43 and a beta of 1.75. The business has a fifty day moving average of $4.77 and a 200-day moving average of $4.26. Organogenesis has a 1 year low of $2.61 and a 1 year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The firm had revenue of $101.01 million during the quarter, compared to analyst estimates of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. Organogenesis has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Organogenesis will post -0.07 EPS for the current year.

Institutional Trading of Organogenesis

Several large investors have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Organogenesis during the 2nd quarter worth about $319,000. Tower Research Capital LLC TRC raised its holdings in shares of Organogenesis by 590.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 23,655 shares of the company's stock worth $87,000 after buying an additional 20,228 shares in the last quarter. Mink Brook Asset Management LLC acquired a new stake in Organogenesis during the 2nd quarter valued at $340,000. First Light Asset Management LLC acquired a new stake in Organogenesis during the 2nd quarter valued at $24,804,000. Finally, Raymond James Financial Inc. increased its stake in shares of Organogenesis by 5.7% in the 2nd quarter. Raymond James Financial Inc. now owns 444,240 shares of the company's stock valued at $1,626,000 after buying an additional 23,919 shares during the period. Institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.